In the present study, we administrated tau antibodies by intravenous injection into 3×Tg-AD mice at a mild stage of the pathology (12 months old) once weekly for up to 6 weeks; 3×Tg-AD mice start developing Aβ plaques at approximately 9 months and tau pathology starts at approximately 12 months [42–44]. Here, MAPT is linked to Alzheimer disease.